Classes
DEA Class; Rx
Common Brand Names; Cinqair
- Interleukin Inhibitors;
- Monoclonal Antibodies, Anti-asthmatics
Description
An intravenously administered humanized monoclonal antibody that targets interleukin 5 and reduces eosinophil-meditated inflammation of the airways
Indicated in adults for add-on maintenance treatment of severe asthma with an eosinophilic phenotype
Anaphylaxis has been reported as early as the second dose; monitor patients closely during and after infusion
Indications
Indicated for asthma maintenance add-on therapy in severe asthma (eosinophilic phenotype).
Contraindications
Known hypersensitivity to reslizumab or its excipients
Adverse Effects
- Elevated CPK, transient (20%)
- Treatment-emergent antibody response (5.4%)
- Oropharyngeal pain (2.6%)
- Musculoskeletal (2.2%)
- Myalgias (1%)
- Elevated CPK >10x ULN (0.8%)
- Malignancy (0.6%)
- Anaphylaxis (0.3%)
Warnings
Anaphylaxis reported observed during or within 20 minutes after completion of the IV infusion and reported as early as the second dose (see Black Box Warnings)
Not for use to treat acute asthma symptoms or acute exacerbations
No clinical studies have been conducted to assess reduction of maintenance corticosteroid dosages following administration of reslizumab; do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of reslizumab therapy
Diverse malignancies observed with reslizumab vs placebo in clinical trials (0.6% vs 0.3%)
Treat patients with pre-existing helminth infections before initiating reslizumab; if patients become infected during reslizumab treatment and do not respond to antihelminth treatment, discontinue reslizumab until infection resolves
Pregnancy and Lactation
Data are insufficient regarding drug-associated risk during pregnancy
Unknown if distributed in human breast milk; however, human IgG is known to be present in human milk
Maximum Dosage
3 mg/kg IV infusion once every 4 weeks.
3 mg/kg IV infusion once every 4 weeks.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
Not indicated.
Not indicated.
How supplied
Reslizumab
IV solution
- 100mg/10mL vial (10mg/mL)
